|
Forecast
Period
|
2025-2029
|
|
Market
Size (2023)
|
USD
6.85 Billion
|
|
Market
Size (2029)
|
USD
11.02 Billion
|
|
CAGR
(2024-2029)
|
8.20%
|
|
Fastest
Growing Segment
|
Epinephrine
|
|
Largest
Market
|
North
America
|
Market Overview
Global Food
Allergy Treatment Market was valued at USD 6.85 Billion in 2023 and is
anticipated to project impressive growth in the forecast period with a CAGR of 8.20%
through 2029. The global food allergy treatment market is witnessing robust
growth, propelled by a combination of factors that are reshaping the landscape
of food allergy care. The rising incidence of food allergies, especially among
children, has heightened demand for advanced therapeutic solutions. This trend
is further accelerated by increased public awareness, more sophisticated
diagnostic tools, and an emphasis on early detection, all of which are driving
market expansion. Diagnostic technologies like skin prick tests and blood tests
have evolved, enabling more accurate and timely identification of allergens,
thereby improving patient management.
A key market
driver is the growing number of food allergy cases worldwide, which is being
met with a surge in innovative treatment modalities. These include oral
immunotherapy (OIT), epinephrine auto-injectors, and monoclonal antibodies,
which target the root causes of allergic reactions and offer more effective
treatment options for patients. Furthermore, food adulteration has emerged as a
significant concern, as it inadvertently introduces allergens into food
products, heightening the need for comprehensive allergy management solutions.
The food allergy treatment market is poised for continued growth, fueled by the
expanding prevalence of food allergies, the development of novel therapies, and
the increasing globalization of diagnostic and treatment protocols. However,
the market must overcome challenges such as limited access to specialized
treatments in certain regions and the growing preference for biosimilars, which
could impact the adoption of newer therapies.
Key Market Drivers
Rising Prevalence of Food
Allergies
The
rising prevalence of food allergies is one of the primary drivers of growth in
the global food allergy treatment market. The increasing number of individuals,
particularly children, diagnosed with food allergies is directly fueling demand
for effective management solutions, creating significant market opportunities.
This phenomenon is occurring on a global scale, with a noticeable uptick in
both developed and developing countries. The prevalence of food allergies has
been steadily increasing, with recent studies estimating that approximately 8%
of children in the United States are affected, and the numbers are rising in
other regions as well. This surge in cases broadens the market for food
allergy treatments, as more individuals require medical interventions. With an
expanding patient pool, pharmaceutical companies and healthcare providers are
prioritizing the development of new treatments, including oral immunotherapies
(OIT), epinephrine auto-injectors, and biologics like monoclonal antibodies,
which target the immune response responsible for these allergic reactions. As
the incidence of food allergies increases, there is a corresponding push for
earlier detection and proactive treatment, which enhances the overall
management of the condition. Advances in diagnostic technologies, such as blood
tests and skin prick tests, are enabling earlier identification of food
allergies, which in turn drives demand for treatment options. Early diagnosis
allows for the implementation of preventive measures and reduces the likelihood
of severe allergic reactions, thus fueling the growth of the treatment market.
As
the awareness surrounding food allergies rises, particularly through media and
health campaigns, both patients and healthcare professionals are more vigilant
about identifying and managing allergies. Parents are becoming more attuned to
the signs of food allergies in children, and adults are increasingly seeking
solutions for managing their conditions. This societal shift is encouraging the
consumption of allergy treatments and driving the demand for more personalized
and accessible therapies. The increasing prevalence of food allergies also
creates a rise in associated healthcare needs, such as emergency treatments for
anaphylaxis (e.g., epinephrine auto-injectors) and ongoing management
solutions. This leads to higher sales volumes for established treatments while
also promoting innovation in more long-term, sustainable therapies like
immunotherapy. Moreover, food manufacturers are responding to this growing need
by offering allergen-free alternatives, contributing to market growth from the
food sector as well. The higher prevalence of food allergies is not confined
to any single demographic group. This growing awareness is expanding across
different age groups, including both young children and adults, especially in
regions like North America, Europe, and increasingly in Asia-Pacific.
Healthcare systems are adapting by incorporating allergy management more
comprehensively into routine care practices, making allergy treatments a core
component of mainstream healthcare. The rising prevalence of food allergies is
a pivotal market driver, as it leads to a broader patient base, higher demand
for early diagnosis, and more specialized treatments. With an increasing
emphasis on proactive allergy management and a growing global awareness, this
trend is significantly accelerating the development of advanced therapeutic
options and solutions, ultimately fueling the global food allergy treatment
market's expansion.
Improved Diagnostic
Technologies
Improved
diagnostic technologies play a crucial role in driving the growth of the global
food allergy treatment market. As food allergies become more prevalent, the
need for accurate, early, and efficient diagnosis has grown significantly.
These advancements in diagnostic tools are facilitating more timely and precise
identification of food allergies, which directly translates into increased
demand for treatment options.
Modern
diagnostic technologies such as skin prick tests, blood tests (e.g., specific
IgE tests), and oral food challenges (OFC) have become more sensitive and
reliable, enabling healthcare providers to identify food allergies earlier in
both children and adults. Early detection allows for more personalized and
effective treatment plans tailored to the specific allergens that trigger an
individual's reactions. This enables patients to receive targeted interventions
such as oral immunotherapy (OIT) or biologics like monoclonal antibodies, which
help desensitize the immune system over time. In addition to traditional
tests, more advanced techniques such as component-resolved diagnostics (CRD)
are being developed. These tests offer a deeper understanding of food allergens
at a molecular level, identifying not just the presence of an allergy but the
specific proteins responsible for the allergic reaction. This precision allows
for more effective and tailored treatments, as patients can be treated based on
the exact nature of their allergy, leading to better outcomes and more
efficient use of medical resources. Improved diagnostic technologies are also
making allergy testing more accessible to a wider population. With the
development of less invasive and more cost-effective tests, healthcare
providers can screen larger patient populations, leading to earlier diagnosis
and, consequently, the early initiation of treatment. This shift is
particularly important in emerging markets where access to healthcare resources
has been limited. Affordable, reliable testing drives demand for treatments as
more people are identified as having food allergies and seek management
solutions.
In
addition to initial diagnosis, advanced diagnostic tools are aiding in the
ongoing monitoring and management of food allergies. Technologies that provide
real-time data on allergen exposure and immune system responses help clinicians
adjust treatment plans dynamically. This is particularly important for
therapies like immunotherapy, where gradual adjustments in treatment intensity
are necessary to maximize efficacy and minimize risks. As a result, improved
diagnostic tools are helping optimize the effectiveness of long-term treatment
protocols, further expanding the market for such treatments. The improvements
in diagnostic accuracy are also driving the development of innovative allergy
treatments. As diagnostic tools become more precise, pharmaceutical companies
are motivated to develop new, more targeted therapies. For example, monoclonal
antibodies like Xolair have been developed to address specific mechanisms in
the allergic response, responding directly to diagnostic insights. This synergy
between diagnostics and therapy fosters the growth of a dynamic treatment
market, which benefits from continuous advancements on both fronts. The
integration of advanced diagnostic tools into healthcare systems allows for
better data collection and analysis, driving a more efficient allergy treatment
process. This is particularly beneficial in regions with well-developed
healthcare infrastructure, such as North America and Europe, where diagnostic
tests are often included as part of routine health assessments. The ability to
track trends, outcomes, and allergic responses on a broader scale further
accelerates innovation in both diagnostics and treatments, driving market
growth. In summary, the continued advancement and refinement of diagnostic
technologies are central to the growth of the global food allergy treatment
market. These innovations enable earlier and more accurate diagnoses, promote
personalized and effective treatment strategies, and facilitate better
management of food allergies. As diagnostics evolve, they create a demand for
more targeted therapies and a broader patient base, which in turn drives the
growth of the treatment market.
Increased Awareness and
Education
Increased
awareness and education around food allergies have become significant catalysts
in the growth of the global food allergy treatment market. As understanding of
the condition expands, both consumers and healthcare professionals are more
proactive in identifying and addressing food allergies, driving demand for
effective treatments and management strategies. Public awareness about the
risks and symptoms of food allergies has grown substantially, thanks to media
campaigns, educational initiatives, and increased dialogue about the condition.
As people become more informed about food allergies, especially in children,
they are actively seeking medical consultations, diagnostic testing, and
treatment solutions. Parents, caregivers, and individuals with food allergies
are now more aware of available treatment options such as epinephrine
auto-injectors, oral immunotherapy, and monoclonal antibodies. This has led to
an increase in the demand for allergy treatments as more individuals and
families seek solutions to manage the condition effectively
With
greater knowledge about the symptoms and risks associated with food allergies,
individuals are more likely to seek medical advice at the first signs of an
allergy. This has led to earlier diagnosis, which is crucial for preventing
severe allergic reactions. As individuals become educated about the importance
of early intervention, there is a rising demand for testing and treatment
options. Educational efforts in schools, communities, and healthcare systems
emphasize the importance of allergy awareness, thereby contributing to the
expansion of the treatment market. This proactive approach helps patients
manage their allergies before they result in life-threatening anaphylactic
reactions. As awareness grows, patients and healthcare professionals are
becoming more receptive to innovative treatments for food allergies.
Historically, treatments were limited to avoiding allergens and using emergency
epinephrine. However, with educational efforts highlighting new therapies such
as oral immunotherapy (OIT) and targeted biologics, there is now more interest
in long-term solutions that can desensitize the immune system and reduce the
severity of allergic reactions. These advancements are gaining traction,
especially as they are actively promoted in educational campaigns, driving
market growth by expanding the range of treatments available. Increased
awareness extends beyond the public to healthcare providers. As food allergy
knowledge improves among medical professionals, there is a greater emphasis on
accurately diagnosing and treating the condition. Physicians, allergists, and
pediatricians are now more likely to offer tailored treatment plans, including
newer therapeutic options, and are better equipped to educate patients on how
to manage their condition effectively. This heightened professionalism and
expertise in food allergy care are driving demand for specialized treatments and
interventions, thereby fueling the growth of the treatment market
As
awareness of food allergies rises, regulatory bodies and public health
organizations are implementing stronger policies to protect individuals with
food allergies. This includes better food labeling, school and workplace
allergy accommodations, and increased funding for food allergy research.
Governments and healthcare organizations are also investing in educational
programs aimed at preventing food allergy reactions and promoting treatment
options. These initiatives not only help raise awareness but also stimulate
demand for better allergy treatments, contributing to the market's expansion. Increased
awareness has also driven demand for allergen-free food products. As more
consumers become aware of food allergies, they are more likely to avoid risky
foods and look for safe, allergen-free alternatives. This shift is prompting
the food industry to offer a wider range of allergy-friendly products, which in
turn increases the need for treatments to manage allergic reactions. This
creates a symbiotic relationship between the food industry and the allergy
treatment market, with both sectors benefiting from heightened awareness. The
rise in awareness and education surrounding food allergies is having a
transformative effect on the global food allergy treatment market. As consumers
become more informed and proactive in seeking treatment, the demand for
advanced therapies, diagnostic tools, and educational resources is expanding.
This shift is not only increasing the market size but also driving innovation
in treatment modalities, further propelling the growth of the sector. The
market's future growth will continue to be fueled by these educational efforts,
resulting in better allergy management and improved quality of life for
patients globally.
Download Free Sample Report
Key Market Challenges
Limited Accessibility to
Specialized Treatments
One
of the most significant barriers to the growth of the food allergy treatment
market is the limited accessibility to specialized treatments, particularly in
low- and middle-income countries. Advanced therapies such as oral immunotherapy
(OIT) and biologics like monoclonal antibodies are not readily available or
affordable in many regions. This disparity is largely due to limited healthcare
infrastructure, insufficient healthcare funding, and a lack of trained
professionals to administer and manage these treatments.
While
these therapies are growing in popularity and effectiveness, their distribution
is concentrated in high-income countries, leaving a significant portion of the
global population without access to cutting-edge food allergy care. In these
regions, many patients are still reliant on basic treatments like epinephrine
auto-injectors and avoidance strategies, which may not provide long-term
solutions or adequate management of severe allergies. This limited
accessibility curtails the global market potential for advanced allergy
treatments.
High Treatment Costs
The
high costs associated with new and advanced food allergy treatments present
another major obstacle. Innovative therapies such as biologics and
immunotherapies can be prohibitively expensive, limiting their accessibility
for the average patient. For example, treatments like Xolair (omalizumab), a
biologic used for managing severe food allergies, can cost thousands of dollars
per year.
Insurance
coverage for these therapies is inconsistent across regions and countries, with
many patients unable to afford the out-of-pocket costs even in well-developed
healthcare systems. The high cost of these therapies, compounded by the need
for long-term treatment regimens (e.g., OIT over several months or years),
presents a significant financial burden on both individuals and healthcare
systems. As a result, many patients may opt for less expensive or less
effective treatments, limiting the market for more advanced options.
Uncertainty and Safety
Concerns with Emerging Therapies
While
emerging therapies such as oral immunotherapy (OIT) and biologics offer
significant promise, they also come with safety concerns and uncertainties
regarding their long-term efficacy. OIT, for instance, carries risks of
allergic reactions during treatment, including anaphylaxis, which can make
patients and healthcare providers hesitant to adopt it widely.
Many
of these treatments are still in the early stages of development or require
ongoing clinical trials to prove their safety and effectiveness across
different populations. The lack of long-term data on these therapies
contributes to uncertainty in their adoption, particularly in regions where
regulatory approvals are stringent. Until these treatments are more thoroughly
vetted and proven safe, there may be reluctance among healthcare providers to
implement them, limiting their uptake and hindering overall market growth.
Key Market Trends
Expansion of Immunotherapy
Treatments
Immunotherapy,
particularly oral immunotherapy (OIT), is a rapidly evolving treatment modality
that is expected to play a pivotal role in the future of food allergy
treatment. OIT involves gradually introducing small amounts of the allergen to
desensitize the immune system, offering the potential for long-term protection
against allergic reactions. This treatment is gaining momentum, with ongoing
research and clinical trials focusing on refining its safety, efficacy, and
applicability across a wider range of allergens
Additionally,
biologics, such as monoclonal antibodies, are gaining prominence for managing
severe food allergies. These therapies target specific immune responses and
have shown promise in clinical settings, particularly for peanut and egg
allergies. As immunotherapy options become more accessible, they are expected
to revolutionize food allergy management, reducing the reliance on emergency
treatments like epinephrine auto-injectors and enabling a more proactive
approach to allergy care.
Advancements in Personalized
and Precision Medicine
Personalized
medicine is a trend gaining significant traction in the food allergy treatment
market. With advances in genetic and molecular diagnostics, healthcare
providers are increasingly able to tailor allergy treatments based on an
individual’s specific genetic makeup, immune response, and the nature of their
allergies. This precision medicine approach allows for more targeted treatments
that minimize risks and improve efficacy.
For
example, the use of biomarkers to predict allergic responses is improving the
accuracy of diagnoses, enabling healthcare providers to better manage treatment
plans. This trend is likely to lead to more effective therapies, fewer side
effects, and faster recovery times for patients. The personalized approach is
particularly important in food allergies, where one-size-fits-all treatments
often fail to address the complex immune mechanisms involved. As the
technology supporting personalized treatments advances, it is expected that the
food allergy treatment market will increasingly embrace these tailored
solutions.
Integration of Digital Health
Technologies
Digital
health technologies, including mobile apps, telemedicine, and wearable devices,
are playing an increasingly vital role in the management of food allergies.
These technologies enable continuous monitoring of allergen exposure, track
allergic reactions, and provide real-time alerts to patients and caregivers.
For instance, wearable devices that track anaphylactic reactions or measure
changes in blood pressure during allergic reactions are becoming more
prevalent, helping to improve emergency responses and overall patient safety.
Mobile
apps are being developed to track food consumption, identify potential
allergens, and connect users with healthcare professionals for advice or
virtual consultations. The integration of artificial intelligence (AI) and
machine learning algorithms into these platforms can further enhance diagnosis
and predict allergic responses based on historical data. As digital health
solutions become more advanced, they are expected to complement traditional
treatment regimens and offer more holistic and continuous care for food allergy
sufferers, driving market growth.
Segmental Insights
Allergen Type Insights
Based
on the category of Allergen Type, the Peanuts segment emerged as the dominant
in the global market for Food Allergy Treatment in 2023. Peanut allergies are
notoriously severe, with reactions often leading to anaphylaxis, a
life-threatening condition that requires immediate intervention. This severity
increases the urgency for more effective treatments, including emergency
interventions like epinephrine auto-injectors, as well as long-term solutions
like immunotherapy to build tolerance to peanuts over time. The high risk
associated with peanut allergies contributes to the growing emphasis on
peanut-specific therapies, pushing the market towards the development of more
specialized and effective treatment options. Peanut allergy treatments have
seen significant progress in recent years. Oral immunotherapy (OIT), where
patients are gradually introduced to peanut protein to desensitize the immune
system, has shown promise in clinical trials, leading to an increase in its
adoption for peanut allergies. The approval of the first peanut allergy
treatment, Palforzia, by the FDA in 2020 marked a significant milestone in the
market. Palforzia is a peanut-derived allergen powder used to desensitize
patients, demonstrating the growth in specific peanut allergy therapies. Additionally,
other treatment options, including biologic therapies like monoclonal
antibodies, are being developed to target the underlying immune mechanisms
responsible for peanut allergies, further driving market expansion in this
segment.
Given
the high prevalence and severity of peanut allergies, a significant portion of
global food allergy research and clinical trials focuses on developing
peanut-specific treatments. Pharmaceutical companies and biotechnology firms
are investing heavily in research to improve the safety, effectiveness, and
accessibility of peanut allergy treatments. These ongoing developments ensure
that the peanut allergy segment remains a focal point for innovation and market
growth, attracting substantial attention from stakeholders across the
healthcare and pharmaceutical industries. There has been a notable increase in
public awareness of peanut allergies, particularly among parents of children,
who are often the primary consumers of allergy treatment products. Media
campaigns, educational initiatives, and advocacy by organizations such as the
Food Allergy Research & Education (FARE) have highlighted the dangers of
peanut allergies, further driving the demand for effective treatments. This
growing awareness not only increases the market demand for peanut allergy
treatments but also encourages the development of allergen-free and peanut-safe
products, contributing to market growth.
Drug Type Insights
Based
on the category of Drug Type, the Epinephrine segment emerged as the dominant
in the global market for Food Allergy Treatment in 2023. Epinephrine, also
known as adrenaline, is the first-line treatment for anaphylaxis, a severe and
potentially life-threatening allergic reaction that can occur in response to
food allergens such as peanuts, shellfish, and milk. It works by rapidly
reversing the symptoms of anaphylaxis, including airway constriction, low blood
pressure, and hives, by stimulating the body's adrenergic receptors. This makes
epinephrine the most effective and widely used treatment in emergency
situations. Given the critical need to act quickly during anaphylaxis,
epinephrine auto-injectors (e.g., EpiPen) have become a staple in managing food
allergies, particularly for individuals who are at high risk of severe
reactions. The dominance of epinephrine in the market is underpinned by its
ability to rapidly stabilize patients and buy time until they can receive
further medical treatment.
Epinephrine
auto-injectors have become a vital part of the standard of care for individuals
with severe food allergies. These devices offer a simple, convenient, and
reliable way for patients or caregivers to administer the drug during an
emergency, even in settings outside of medical facilities. The growing adoption
of epinephrine auto-injectors is driving the segment's dominance in the market,
as they are recommended for anyone with a history of severe allergic reactions.
The commercial success of epinephrine auto-injectors like EpiPen has led to
increased competition in the market, with multiple brands now available to meet
the demand. As awareness of the importance of carrying an epinephrine
auto-injector rises, especially among parents of children with food allergies,
the market for these devices continues to expand. Furthermore, initiatives from
health organizations to educate the public about anaphylaxis and proper
epinephrine usage have bolstered demand for these products.
Epinephrine’s
dominant position in the food allergy treatment market is also supported by
regulatory frameworks that ensure its accessibility and affordability. In many
countries, including the United States and European nations, epinephrine
auto-injectors are covered by insurance plans and are prescribed widely by
healthcare providers. This broad insurance coverage reduces the financial
burden on patients, making epinephrine treatment more accessible and
reinforcing its place as the standard treatment for food allergies. Additionally,
schools, workplaces, and public spaces are increasingly required by law to have
epinephrine on hand, further solidifying its dominance in the market.
Legislative changes, such as those mandating that schools stock epinephrine for
emergency use, have made these devices more ubiquitous, ensuring that they are
easily available during allergic emergencies, even outside of the home setting.
Download Free Sample Report
Regional Insights
North
America emerged as the dominant in the global Food Allergy Treatment market in
2023, holding the largest market share in terms of value. Food allergies are
more prevalent in North America compared to other regions, particularly among
children. In the U.S., it is estimated that about 8% of children have a food
allergy, with peanuts, milk, and shellfish being the most common allergens.
This high prevalence drives the demand for food allergy treatments, including
epinephrine auto-injectors, oral immunotherapy (OIT), and biologics. The
substantial patient population in North America ensures a constant need for
allergy management solutions, fueling growth in the market. Additionally,
rising awareness about food allergies among the general population, parents,
and healthcare providers in North America has resulted in an increased
willingness to seek treatment options and manage the condition more
effectively. This heightened awareness, combined with the increasing number of
diagnosed cases, creates a strong and sustained demand for food allergy
treatments.
North
America benefits from well-established healthcare systems and regulatory
frameworks that support the development, approval, and distribution of
innovative allergy treatments. The U.S. Food and Drug Administration (FDA) has
approved numerous allergy treatments, including the first oral immunotherapy
product for peanut allergies (Palforzia), and epinephrine auto-injectors (e.g.,
EpiPen) are widely prescribed and available. The regulatory environment in
North America encourages the rapid approval and commercialization of new
treatments, ensuring that patients have access to the latest therapies. The
healthcare infrastructure in North America is robust, with widespread access to
specialized allergy care, including allergists and immunologists, who play a
critical role in diagnosing and managing food allergies. This ensures that
patients receive timely and effective treatments, further driving market demand
for food allergy therapies. The availability of advanced diagnostics and
treatment options also boosts the market in this region
North
America, particularly the U.S., is a global leader in pharmaceutical research
and development (R&D). The region is home to major pharmaceutical and
biotechnology companies, such as Regeneron Pharmaceuticals, Sanofi, and Aimmune
Therapeutics, which invest heavily in food allergy treatment innovations.
Research in immunotherapy, biologics, and other novel therapies is concentrated
in North America, with clinical trials and studies often conducted in the
region before global expansion. The extensive R&D investment results in the
rapid development of new treatments tailored to the needs of food allergy
patients, further strengthening the market in North America. The region's focus
on developing peanut-specific therapies, including OIT and monoclonal
antibodies, contributes to its dominant role in the market. As North American
companies continue to innovate and bring new solutions to market, the region is
poised to maintain its leadership in the global food allergy treatment
landscape.
Recent Developments
- In
October 2024- DBV Technologies, a clinical-stage biopharmaceutical company,
announced significant regulatory progress for its Viaskin Peanut patch in both
the U.S. and Europe. The company has aligned with the U.S. Food and Drug
Administration (FDA) on a proposed pathway for the patch’s Accelerated Approval
Program targeting toddlers aged 1 to 3 years. In addition, DBV received
scientific advice from the European Medicines Agency (EMA) for a similar
indication for children aged 1 to 7 years in Europe. DBV plans to formalize the
FDA's guidance by submitting a meeting request to advance the regulatory
process for the Viaskin Peanut patch.
- In
July 2024, Stallergenes Greer, a global leader in allergen immunotherapy,
announced today that the U.S. Food and Drug Administration (FDA) has approved Palforzia®
(Peanut [Arachis hypogaea] Allergen Powder-dnfp) for the treatment of toddlers
aged 1 to 3 years with a confirmed peanut allergy. This approval extends the January
2020 FDA approval for patients aged 4 to 17 years. Palforzia® remains the first
and only FDA-approved oral immunotherapy (OIT) for the mitigation of allergic
reactions, including anaphylaxis, caused by accidental peanut exposure.
- In
February 2024, Novartis announced that the U.S. Food and Drug Administration
(FDA) has approved Xolair® (omalizumab) for the reduction of allergic
reactions, including anaphylaxis, resulting from accidental exposure to one or
more foods in both adult and pediatric patients aged 1 year and older with
IgE-mediated food allergies. Xolair® is now the first and only FDA-approved
medication specifically designed to reduce allergic reactions caused by food
allergies. However, patients using Xolair must continue to avoid consuming
foods they are allergic to, as the drug is not intended for emergency use,
including the treatment of anaphylaxis.
Key Market Players
- Sanofi
- STALLERGENES
GREER International AG
- DBV
Technologies
- Vedanta
Biosciences, Inc.
- Alladapt
Immunotherapeutics, Inc.
- COUR
Pharmaceuticals Development Company, Inc
- Aravax
- Prota
Therapeutics Pty Ltd
- Teva
Pharmaceutical Industries Ltd.
- F.
Hoffmann-La Roche Ltd
|
By
Allergen Type
|
By
Drug Type
|
By
Route of Administration
|
By
End User
|
By
Region
|
- Dairy
Products
- Poultry
Product
- Tree
Nuts
- Peanuts
- Shellfish
- Wheat
- Soys
- Other
|
- Antihistamines
- Epinephrine
- Immunotherapy
|
|
- Hospital
Pharmacies
- Retail
Pharmacies
- Others
|
- North
America
- Europe
- Asia
Pacific
- South
America
- Middle
East & Africa
|
Report Scope:
In this report, the Global Food Allergy Treatment
Market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
- Food Allergy Treatment Market, By Allergen Type:
o Dairy Products
o Poultry Product
o Tree Nuts
o Peanuts
o Shellfish
o Wheat
o Soys
o Other
- Food Allergy Treatment Market, By Drug Type:
o Antihistamines
o Epinephrine
o Immunotherapy
- Food Allergy Treatment Market, By Rout of Administration:
o Oral
o Parenteral
o Other
- Food Allergy Treatment Market, By End User:
o Hospital Pharmacies
o Retail Pharmacies
o Others
- Food Allergy Treatment Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Food
Allergy Treatment Market.
Available Customizations:
Global Food Allergy Treatment market report
with the given market data, TechSci Research offers customizations according
to a company's specific needs. The following customization options are
available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Global Food Allergy
Treatment Market is an upcoming report to be released soon. If you wish an
early delivery of this report or want to confirm the date of release, please
contact us at [email protected]